Genome And Co (314130)

Currency in KRW
7,340
+280(+3.97%)
Closed·
314130 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7,0907,640
52 wk Range
2,44010,180
Key Statistics
Bid/Ask
7,330.00 / 7,340.00
Prev. Close
7,060
Open
7,330
Day's Range
7,090-7,640
52 wk Range
2,440-10,180
Volume
463.58K
Average Volume (3m)
627.22K
1-Year Change
168.8645%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
314130 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Genome And Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 20, 2026
EPS / Forecast
453.96 / --
Revenue / Forecast
5.87B / --
EPS Revisions
Last 90 days

314130 Income Statement

Compare 314130 to Peers and Sector

Metrics to compare
314130
Peers
Sector
Relationship
P/E Ratio
−39.8x−11.5x−0.5x
PEG Ratio
−0.58−0.060.00
Price/Book
2.5x3.0x2.6x
Price / LTM Sales
10.4x11.7x3.3x
Upside (Analyst Target)
-54.1%47.7%
Fair Value Upside
Unlock11.8%6.6%Unlock

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
39.75K0.11%291.77M
Other Institutional Investors
14.19M40.67%104.15B
Public Companies & Retail Investors
20.66M59.22%151.67B
Total
34.89M100.00%256.11B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Intervest Open Innovation Private Equity Fund6.69%2,334,62817,136,170
DSC Investment4.14%1,446,24810,615,460

People Also Watch

58,500
263750
-0.68%
32,150
047040
-8.14%
539,000
005380
+1.51%

FAQ

What Is the Genome (314130) Stock Price Today?

The Genome stock price today is 7,340 KRW.

What Stock Exchange Does Genome Trade On?

Genome is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Genome?

The stock symbol for Genome is "314130."

What Is the Genome Market Cap?

As of today, Genome market cap is 256.11B KRW.

What Is Genome's Earnings Per Share (TTM)?

The Genome EPS (TTM) is -205.

From a Technical Analysis Perspective, Is 314130 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Genome Stock Split?

Genome has split 1 times.

What is the current trading status of Genome (314130)?

As of May 04, 2026, Genome (314130) is trading at a price of 7,340 KRW, with a previous close of 7,060 KRW. The stock has fluctuated within a day range of 7,090 KRW to 7,640 KRW, while its 52-week range spans from 2,440 KRW to 10,180 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.